{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:03:14Z","timestamp":1789646594947,"version":"4.0.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.beem.2013.12.001","type":"journal-article","created":{"date-parts":[[2013,12,17]],"date-time":"2013-12-17T21:30:18Z","timestamp":1387315818000},"page":"325-338","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":87,"title":["Lipids and lipid management in diabetes"],"prefix":"10.1016","volume":"28","author":[{"given":"Mamta","family":"Jaiswal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Schinske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodica","family":"Pop-Busui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.beem.2013.12.001_bib1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.diabres.2011.10.029","article-title":"IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030","volume":"94","author":"Whiting","year":"2011","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"10.1016\/j.beem.2013.12.001_bib2","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1210\/jcem.86.3.7304","article-title":"Diabetic Dyslipidemia: Causes and Consequences","volume":"86","author":"Goldberg","year":"2001","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2013.12.001_bib3","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1161\/CIRCULATIONAHA.108.829176","article-title":"Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005","volume":"119","author":"Preis","year":"2009","journal-title":"Circulation"},{"issue":"7347","key":"10.1016\/j.beem.2013.12.001_bib4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nature10146","article-title":"Progress and challenges in translating the biology of atherosclerosis","volume":"473","author":"Libby","year":"2011","journal-title":"Nature"},{"issue":"23","key":"10.1016\/j.beem.2013.12.001_bib5","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1001\/jama.1987.03390230069027","article-title":"Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts","volume":"257","author":"Blankenhorn","year":"1987","journal-title":"J\u00a0Am Med Assoc"},{"issue":"20","key":"10.1016\/j.beem.2013.12.001_bib6","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2013.12.001_bib7","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2337\/diacare.16.2.434","article-title":"Diabetes, other risk factors and 12\u2013year cardiovascular mortality for men screened in the multiple risk factor intervention trial","volume":"16","author":"Stamler","year":"1993","journal-title":"Diabetes Care"},{"key":"10.1016\/j.beem.2013.12.001_bib8","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/0002-8703(85)90224-8","article-title":"Lipids, diabetes, and coronary heart disease: insights from the Framingham Study","volume":"110","author":"Kannel","year":"1985","journal-title":"Am Heart J"},{"key":"10.1016\/j.beem.2013.12.001_bib9","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2337\/diacare.29.02.06.dc05-1904","article-title":"Diabetes and coronary risk equivalency: what does it mean?","volume":"29","author":"Grundy","year":"2006","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.beem.2013.12.001_bib10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jpeds.2012.06.006","article-title":"Glucose control predicts 2-year change in lipid profile in youth with type 1 diabetes","volume":"162","author":"Maahs","year":"2013","journal-title":"J\u00a0Pediatr"},{"issue":"3","key":"10.1016\/j.beem.2013.12.001_bib11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.diabres.2005.03.032","article-title":"Prevalence and control of dyslipidemia among persons with diabetes in the United States","volume":"70","author":"Jacobs","year":"2005","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"10.1016\/j.beem.2013.12.001_bib12","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ecl.2006.06.002","article-title":"Diabetic dyslipidemia","volume":"35","author":"Chahil","year":"2006","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"4","key":"10.1016\/j.beem.2013.12.001_bib13","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1464-5491.2010.02956.x","article-title":"Temporal patterns in overweight and obesity in Type 1 diabetes","volume":"27","author":"Conway","year":"2010","journal-title":"Diabet Med"},{"issue":"6","key":"10.1016\/j.beem.2013.12.001_bib14","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1507\/endocrj.K08E-167","article-title":"Association between body mass index and core components of metabolic syndrome in 1486 patients with type 1 diabetes mellitus in Japan (JDDM 13)","volume":"55","author":"Arai","year":"2008","journal-title":"Endocr J"},{"issue":"8","key":"10.1016\/j.beem.2013.12.001_bib15","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.2337\/diacare.21.8.1258","article-title":"Adverse effects of diabetes on multiple cardiovascular disease risk factors in women. The Strong Heart Study","volume":"21","author":"Howard","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1016\/j.beem.2013.12.001_bib16","first-page":"1","article-title":"Lipids, glucose intolerance and vascular disease: the Framingham Study","volume":"13","author":"Wilson","year":"1985","journal-title":"Monogr Atheroscler"},{"issue":"6","key":"10.1016\/j.beem.2013.12.001_bib17","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.2337\/diacare.27.6.1496","article-title":"Lipids and lipoproteins in patients with type 2 diabetes","volume":"27","author":"Krauss","year":"2004","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.beem.2013.12.001_bib18","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1161\/01.ATV.0000156537.78366.1d","article-title":"Increased ApoB in small dense LDL particles predicts premature coronary artery disease","volume":"25","author":"Brunzell","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"10","key":"10.1016\/j.beem.2013.12.001_bib19","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1210\/jc.2003-030636","article-title":"Clinical review 163: cardiovascular endocrinology: low-density lipoprotein size and cardiovascular disease: a reappraisal","volume":"88","author":"Sacks","year":"2003","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2013.12.001_bib20","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1161\/01.CIR.101.9.975","article-title":"Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state","volume":"101","author":"Haffner","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.beem.2013.12.001_bib21","doi-asserted-by":"crossref","first-page":"390","DOI":"10.2337\/diacare.19.4.390","article-title":"Acute effects of insulin in the control of VLDL production in humans. Implications for the insulin-resistant state","volume":"19","author":"Lewis","year":"1996","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.beem.2013.12.001_bib22","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1194\/jlr.R200015-JLR200","article-title":"Lipoprotein lipase: genetics, lipid uptake, and regulation","volume":"43","author":"Merkel","year":"2002","journal-title":"Lipid Res"},{"issue":"8","key":"10.1016\/j.beem.2013.12.001_bib23","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1210\/jc.2003-032056","article-title":"Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity","volume":"89","author":"Cohn","year":"2004","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.beem.2013.12.001_bib24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1001\/jama.1995.03520260035025","article-title":"LDL density and atherosclerosis","volume":"273","author":"Austin","year":"1995","journal-title":"J\u00a0Am Med Assoc"},{"issue":"1","key":"10.1016\/j.beem.2013.12.001_bib25","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/ajcn\/77.1.43","article-title":"Hepatic de novo lipogenesis in normo-insulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets","volume":"77","author":"Schwarz","year":"2003","journal-title":"Am J Clin Nutr"},{"issue":"5","key":"10.1016\/j.beem.2013.12.001_bib26","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J\u00a0Clin Invest"},{"issue":"4","key":"10.1016\/j.beem.2013.12.001_bib27","doi-asserted-by":"crossref","first-page":"e001206","DOI":"10.1161\/JAHA.112.001206","article-title":"Trends in clinical, demographic, and biochemical characteristics of patients with acute myocardial infarction from 2003 to 2008: a report from the american heart association get with the guidelines coronary artery disease program","volume":"1","author":"Boyer","year":"2012","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"10","key":"10.1016\/j.beem.2013.12.001_bib28","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.2337\/diacare.28.10.2508","article-title":"Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial","volume":"28","author":"Schwartz","year":"2005","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.beem.2013.12.001_bib29","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ahj.2005.11.011","article-title":"Metabolic syndrome, C-reactive protein, and prognosis in patients with established coronary artery disease","volume":"152","author":"Aguilar","year":"2006","journal-title":"Am Heart J"},{"issue":"9539","key":"10.1016\/j.beem.2013.12.001_bib30","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(06)69292-1","article-title":"Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the treating to new targets study","volume":"368","author":"Deedwania","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2013.12.001_bib31","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1161\/CIRCULATIONAHA.106.658948","article-title":"Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study","volume":"115","author":"Fox","year":"2007","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.beem.2013.12.001_bib32","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/2012","article-title":"Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts","volume":"4","author":"Park","year":"1998","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.beem.2013.12.001_bib33","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1161\/01.ATV.17.10.2250","article-title":"Effect of streptozotocin-induced hyperglycemia on lipid profiles, formation of advanced glycation endproducts in lesions, and extent of atherosclerosis in LDL receptor-deficient mice","volume":"17","author":"Reaven","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"10.1016\/j.beem.2013.12.001_bib34","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1161\/01.ATV.19.12.2981","article-title":"Dyslipidemia and vascular dysfunction in diabetic pigs fed an atherogenic diet","volume":"19","author":"Dixon","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.beem.2013.12.001_bib35","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/bmj.316.7134.823","article-title":"Risk factors for coronary artery disease in non\u2013insulin dependent diabetes mellitus: United Kingdom prospective diabetes study","volume":"316","author":"Turner","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.beem.2013.12.001_bib36","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection E, And treatment of high blood cholesterol in Adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.beem.2013.12.001_bib37","doi-asserted-by":"crossref","first-page":"4,811","DOI":"10.2337\/dc08-9018","article-title":"Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American diabetes association and the American college of cardiology foundation","volume":"31","author":"Brunzell","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.beem.2013.12.001_bib38","article-title":"ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults a report of the american college of Cardiology\/American heart association Task Force on Practice guidelines","author":"Stone","year":"2013","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.beem.2013.12.001_bib39","doi-asserted-by":"crossref","first-page":"421","DOI":"10.7326\/0003-4819-141-6-200409210-00007","article-title":"Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus","volume":"141","author":"Selvin","year":"2004","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.beem.2013.12.001_bib40","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1007\/s00125-005-1858-4","article-title":"The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis","volume":"48","author":"Gerstein","year":"2005","journal-title":"Diabetologia"},{"issue":"7258","key":"10.1016\/j.beem.2013.12.001_bib41","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"issue":"9131","key":"10.1016\/j.beem.2013.12.001_bib42","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","year":"1998","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.beem.2013.12.001_bib43","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.beem.2013.12.001_bib44","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.beem.2013.12.001_bib45","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1056\/NEJMoa052187","article-title":"Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes","volume":"353","author":"Nathan","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.beem.2013.12.001_bib46","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"7160","key":"10.1016\/j.beem.2013.12.001_bib47","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS UK Prospective Diabetes Study Group","volume":"317","year":"1998","journal-title":"BMJ"},{"issue":"Suppl. 2","key":"10.1016\/j.beem.2013.12.001_bib48","first-page":"B49","article-title":"Lipid intervention trials in diabetes","volume":"23","author":"Steiner","year":"2000","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.beem.2013.12.001_bib49","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.beem.2013.12.001_bib50","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl. 1","key":"10.1016\/j.beem.2013.12.001_bib51","first-page":"S83","article-title":"Management of dyslipidemia in adults with diabetes","volume":"26","author":"Haffner","year":"2003","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.beem.2013.12.001_bib52","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/qjmed\/hcq165","article-title":"Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials","volume":"104","author":"Mills","year":"2011","journal-title":"QJM \u2013 Monthly Journal of the Association of Physicians"},{"issue":"4","key":"10.1016\/j.beem.2013.12.001_bib53","doi-asserted-by":"crossref","first-page":"614","DOI":"10.2337\/diacare.20.4.614","article-title":"Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)","volume":"20","author":"Py\u014fr\u00e4l\u00e4","year":"1997","journal-title":"Diabetes Care"},{"issue":"9374","key":"10.1016\/j.beem.2013.12.001_bib54","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"issue":"9435","key":"10.1016\/j.beem.2013.12.001_bib55","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.beem.2013.12.001_bib56","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.2337\/dc05-2415","article-title":"Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN)","volume":"29","author":"Knopp","year":"2006","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.beem.2013.12.001_bib57","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2337\/diacare.28.5.1151","article-title":"Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial\u2013lipid-lowering arm (ASCOT-LLA)","volume":"28","author":"Sever","year":"2005","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.beem.2013.12.001_bib58","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ahj.2004.03.067","article-title":"Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention\u2013a Lescol Intervention Prevention Study (LIPS) substudy","volume":"149","author":"Arampatzis","year":"2005","journal-title":"Am Heart J"},{"issue":"6","key":"10.1016\/j.beem.2013.12.001_bib59","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.2337\/dc05-2465","article-title":"Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study","volume":"29","author":"Shepherd","year":"2006","journal-title":"Diabetes Care"},{"issue":"15","key":"10.1016\/j.beem.2013.12.001_bib60","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2013.12.001_bib61","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent C","year":"2010","journal-title":"Lancet"},{"issue":"9716","key":"10.1016\/j.beem.2013.12.001_bib62","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.beem.2013.12.001_bib63","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"J\u00a0Am Med Assoc"},{"issue":"21","key":"10.1016\/j.beem.2013.12.001_bib64","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"9841","key":"10.1016\/j.beem.2013.12.001_bib65","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(12)61190-8","article-title":"Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial","volume":"380","author":"Ridker","year":"2012","journal-title":"Lancet"},{"issue":"9841","key":"10.1016\/j.beem.2013.12.001_bib66","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2013.12.001_bib67","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/bmj.38678.389583.7C","article-title":"Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies","volume":"332","author":"Huxley","year":"2006","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.beem.2013.12.001_bib68","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1185\/03007995.2012.657302","article-title":"Daily and intermittent rosuvastatin 5\u2009mg therapy in statin intolerant patients: an observational study","volume":"28","author":"Meek","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.beem.2013.12.001_bib69","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the american college of Cardiology\/American heart association Task Force on Practice Guidelines","author":"Goff","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.beem.2013.12.001_bib70","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.beem.2013.12.001_bib71","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.beem.2013.12.001_bib72","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1136\/hrt.40.10.1069","article-title":"A\u00a0co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators","volume":"40","author":"Report from the Committee of Principal Investigators","year":"1978","journal-title":"Br Heart J"},{"issue":"1","key":"10.1016\/j.beem.2013.12.001_bib73","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","article-title":"Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease","volume":"102","author":"Bezafibrate Infarction Prevention (BIP) Study","year":"2000","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.beem.2013.12.001_bib74","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1161\/01.CIR.92.7.1779","article-title":"Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study","volume":"92","author":"Tenkanen","year":"1995","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.beem.2013.12.001_bib75","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1161\/CIRCULATIONAHA.105.620450","article-title":"Cardioprotective properties of fibrates: which fibrate, which patients, what mechanism?","volume":"113","author":"Barter","year":"2006","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.beem.2013.12.001_bib76","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1001\/archinte.165.10.1154","article-title":"Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome","volume":"165","author":"Tenenbaum","year":"2005","journal-title":"Arch Intern Med"},{"issue":"9500","key":"10.1016\/j.beem.2013.12.001_bib77","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2013.12.001_bib78","article-title":"Comparison of statin alone versus bezafibrate and statin combination in patients with diabetes mellitus and acute coronary syndrome","author":"Klempfner","year":"2013","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.beem.2013.12.001_bib79","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.beem.2013.12.001_bib80","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jama.284.10.1263","article-title":"Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial","volume":"284","author":"Elam","year":"2000","journal-title":"J\u00a0Am Med Assoc"},{"issue":"14","key":"10.1016\/j.beem.2013.12.001_bib81","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/archinte.162.14.1568","article-title":"Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial","volume":"162","author":"Grundy","year":"2002","journal-title":"Arch Intern Med"},{"issue":"24","key":"10.1016\/j.beem.2013.12.001_bib82","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"AIM-HIGH Investigators","year":"2011","journal-title":"N\u00a0Engl J Med"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X13001838?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X13001838?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:47:16Z","timestamp":1761497236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X13001838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":82,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S1521690X13001838"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2013.12.001","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipids and lipid management in diabetes","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2013.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}